PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
March 18, 2024 14:37 ET | PRISM MarketView
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
March 07, 2024 15:23 ET | PRISM MarketView
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
finacialnews-logo-final-01 (2).png
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024 08:30 ET | FN Media Group LLC
PALM BEACH, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer...
Transparency Market Research
Biopharmaceutical Fermentation Systems Market Projected to Reach USD 52.6 billion by 2031, with a CAGR of 9.5%: Report by Transparency Market Research Inc.
March 01, 2024 01:32 ET | Transparency Market Research
Wilmington, Delaware, United States, March 01, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global biopharmaceutical fermentation systems market is projected to grow at a CAGR of...
PMV main logo.png
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day
February 29, 2024 09:54 ET | PRISM MarketView
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day
ocugen_4C_LOGO (002).png
Ocugen Clinical Showcase Webcast Now Available
February 28, 2024 08:00 ET | Ocugen
MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
LOGO.png
GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
February 27, 2024 07:45 ET | The Greater Cannabis Company, Inc.
BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation...
ocugen_4C_LOGO (002).png
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
February 26, 2024 08:30 ET | Ocugen
MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Logo 1.png
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
February 26, 2024 07:30 ET | Aeterna Zentaris Inc
ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and...
finacialnews-logo-final-01 (2).png
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
February 15, 2024 08:45 ET | FN Media Group LLC
PALM BEACH, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Numerous reports indicate that the fibromyalgia treatment market is positioned to continue to grow at a...